Evidence map›Paper›PMID 19179212›Full record

ReviewJournal of the American College of Cardiology2009

Insulin as an anti-inflammatory and antiatherogenic modulator.

Paresh Dandona, Ajay Chaudhuri, Husam Ghanim, Priya Mohanty

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of the American College of Cardiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01524705 phase4completedstarted 2012, after this paper: background citation

FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR

Ran2012Enrolled102Registered outcomes4Posted comparisons3ConditionsType 2 DiabetesArmsexenatide, Insulin glargine, Metformin, Prandial insulin
Open the trial in the graph
NCT03328845 phase4completednot on this mapstarted 2017, after this paper: background citation

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study)

TypeinterventionalSponsorFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludRan2017 to 2021Enrolled300ConditionsType 1 Diabetes MellitusArmsToujeo SoloStar, Tresiba, Humalog Kwikpen, NovoRapid, Apidra
3 · Its place in the literature

Who cites it

64 citing papers in PubMed.

  1. Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020
    Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Paresh DandonaKaleida Health, Buffalo, New York, USA. pdandona@kaleidahealth.org
Ajay Chaudhuri
Husam Ghanim
Priya Mohanty

Funding

Inflammation in obesity: Modulation by Weight LossR01DK069805 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DANDONA, PARESH · 2005 to 2009
$1.5M
NIDDK NIH HHS R01 DK069805
6 · The paper itself

Abstract

Data demonstrate the anti-inflammatory effects of insulin and proinflammatory effects of glucose. These data provide a mechanistic justification for the benefits of maintaining euglycemia with insulin infusions in hospitalized patients. Regimens that infuse fixed doses of insulin with high rates of glucose are usually associated with hyperglycemia, which may neutralize the beneficial effects of insulin. Therefore, we propose that such regimens should be avoided and instead replaced by insulin infusions that normalize and maintain blood glucose at a reasonably low level and ensure that plasma insulin is maintained at levels high enough to provide clinically relevant anti-inflammatory and cardioprotective effects. Trials to test this hypothesis are in progress.

Indexed as

Acute Coronary SyndromeAnticholesteremic AgentsAnti-Inflammatory AgentsBlood GlucoseDiabetes ComplicationsDiabetes MellitusHumansHyperglycemiaHypoglycemic AgentsInflammationInfusions, IntravenousInsulinOxidative StressAnticholesteremic AgentsAnti-Inflammatory AgentsBlood GlucoseHypoglycemic AgentsInsulin

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.